Last reviewed · How we verify
Placebo、Chemotherapeutic
This is a placebo control used in chemotherapy clinical trials to establish efficacy of an active chemotherapeutic agent.
This is a placebo control used in chemotherapy clinical trials to establish efficacy of an active chemotherapeutic agent. Used for Control arm in chemotherapy clinical trial (specific indication unknown).
At a glance
| Generic name | Placebo、Chemotherapeutic |
|---|---|
| Sponsor | Jiangsu HengRui Medicine Co., Ltd. |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Placebo serves as the inactive comparator arm in phase 3 trials to measure the true therapeutic benefit of the investigational chemotherapeutic drug against no active treatment. The actual mechanism of the active chemotherapeutic agent is not specified in the provided information.
Approved indications
- Control arm in chemotherapy clinical trial (specific indication unknown)
Common side effects
Key clinical trials
- A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer (PHASE1, PHASE2)
- Coenzyme Q10 and Chemotherapeutic Toxicity in Breast Cancer Patients (PHASE2)
- Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012) (PHASE3)
- Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer (PHASE2)
- Use of Chinese Herbal Formula Shu Yu Wan in Lung Cancer Patients (NA)
- A Novel Approach for Alleviating the Side Effects of Chemotherapeutic Agents. (PHASE2)
- A Randomized Trial of Chemotherapy in Surgical Patients With Infiltrating Ductal Carcinoma of Breast (PHASE1)
- SON-080 in Patients With Persistent Chemotherapy-induced Peripheral Neuropathy (CIPN) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo、Chemotherapeutic CI brief — competitive landscape report
- Placebo、Chemotherapeutic updates RSS · CI watch RSS
- Jiangsu HengRui Medicine Co., Ltd. portfolio CI